AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15198156
Drug: Spinal anaesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anaesthesia (15 mg bupivacaine heavy + 50 microg fentanyl)
Trial: 15198156
Drug: Saddle blockade
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saddle blockade (10 mg bupivacaine heavy + 50 microg fentanyl)
Trial: 6347154
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no adjuvant immunotherapy)
Trial: 27381275
Drug: Liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8 mg/d
Trial: 19607731
Drug: MSP3 malaria
RxNorm normalized name: PLASMODIUM MALARIAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSP3 malaria vaccine (15 microg)
Trial: 19607731
Drug: MSP3 malaria
RxNorm normalized name: PLASMODIUM MALARIAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSP3 malaria vaccine (30 microg)
Trial: 7852065
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine sulfate (morphine)
Trial: 356764
Drug: Indomethacin suppositories
RxNorm normalized name: Indomethacin Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin suppositories
Trial: 23645695
Drug: L-arginine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (100 mg/kg tid)
Trial: 18347491
Drug: Antibiotics (cephalexin)
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (cephalexin)
Trial: 3544968
Drug: TECA 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TECA 120 mg/day
Trial: 31994196
Drug: Phentolamine mesylate
RxNorm normalized name: Phentolamine Mesylate
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phentolamine mesylate (1.7-mL OraVerse, 0.4-mg)
Trial: 29651711
Drug: Baclofen 45-60
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baclofen 45-60 mg/day for 3 months (n=37)
Trial: 29651711
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU, n=70)
Trial: 19902491
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents with IVUS guidance
Trial: 17259789
Drug: T4-Ibsa oral
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: T4-Ibsa oral solution
Trial: 1343144
Drug: CMF and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF and TMF chemotherapy
Trial: 4068237
Drug: N-CWS immunotherapy
RxNorm normalized name: N-ethylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-CWS immunotherapy
Trial: 24882841
Drug: Control kinesiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control kinesiotherapy (using common daily-life objects)
Trial: 19525335
Drug: Nabilone 1-3
RxNorm normalized name: nabilone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone 1-3 mg
Trial: 18718641
Drug: Dutasteride (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride (0.5 mg/d) for 3 months
Trial: 18718641
Drug: Dutasteride (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride (0.5 mg/d) for 1-4 months
Trial: 21093145
Drug: Dutasteride (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride (0.5 mg/d)
Trial: 15823654
Drug: Hand rubbing
RxNorm normalized name: ALCOHOL 0.8 TOPICAL SPRAY [Hand Rub]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand rubbing with an alcoholic solution
Trial: 85812
Drug: Intravenous aminoacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous aminoacid infusion
Trial: 814825
Drug: Intravenous hyperalimentation
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hyperalimentation
Trial: 25530275
Drug: Propofol combined
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol combined with 40% nitrous oxide inhalation (group N+P)
Trial: 8796365
Drug: Amiodarone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone treatment for 6 months
Trial: 30721652
Drug: Premature Infant
RxNorm normalized name: Premature infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premature Infant Oral Motor Intervention (PIOMI) once daily for 7 consecutive days
Trial: 26650971
Drug: RBP-6000 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBP-6000 (300 mg)
Trial: 26650971
Drug: Hydromorphone (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (6 mg, 18 mg)
Trial: 20722559
Drug: Considering eGFR
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Considering eGFR level less than 60 mL/min/1.73 m² as high risk for CIN
Trial: 20722559
Drug: Considering eGFR
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Considering eGFR level less than 30 mL/min/1.73 m² as high risk for CIN
Trial: 10073841
Drug: Subcutaneous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous vitamin K1
Trial: 7721614
Drug: Diethylstilbestrol 1
RxNorm normalized name: diethylstilbestrol 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylstilbestrol 1 mg three times per day by mouth
Trial: 30678676
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of access to the Big White Wall (BWW) (n=57)
Trial: 29432076
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy using paclitaxel and carboplatin (3 cycles, once every 3 weeks) followed by radical hysterectomy
Trial: 29432076
Drug: Concomitant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant chemoradiation with standard cisplatin-based treatment (once every week for 5 weeks)
Trial: 29432076
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy plus surgery
Trial: 26694501
Drug: Concurrent Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Training (CT) - 4 sets of 30-s maximal effort, separated by 4 m 30-s rest intervals
Trial: 23654003
Drug: Acetazolamide 250
RxNorm normalized name: acetazolamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 250 mg administered 1 hour and 24 hours after phacoemulsification (Group I)
Trial: 23654003
Drug: Acetazolamide 250
RxNorm normalized name: acetazolamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 250 mg (Group I)
Trial: 20591614
Drug: Spiritually Integrated
RxNorm normalized name: Spiritus vini
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spiritually Integrated Treatment (SIT)
Trial: 17956647
Drug: EPA+DHA supplementation
RxNorm normalized name: eicosapentaenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA+DHA supplementation (1.5 g/d)
Trial: 8751166
Drug: Oxygen saturation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen saturation (Sao2) before medication
Trial: 8751166
Drug: Oxygen saturation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen saturation (Sao2) after medication
Trial: 31791396
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy for insomnia (CBTi) - six sessions
Trial: 20971535
Drug: CCD (preOp(®),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCD (preOp(®), Nutricia, UK, 50 g carbohydrate)
Trial: 20971535
Drug: CCD/L (preOp(®),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCD/L (preOp(®), 36 g carbohydrate + 7 g lipid)
Trial: 20971535
Drug: CCD/G
RxNorm normalized name: Calcium Carbonate/Cholecalciferol/Glucosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCD/G
Trial: 20971535
Drug: CCD/L
RxNorm normalized name: Calcium Carbonate/Cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCD/L
Trial: 17827461
Drug: Conventional cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cytotoxic drugs or increased radiation dose
Trial: 9676350
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily administration of sustained release theophylline
Trial: 7986180
Drug: Adjunctive oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive oral cabergoline
Trial: 2733574
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (320 mg ferrous sulfate)
Trial: 31575825
Drug: Caffeine 4
RxNorm normalized name: caffeine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 4 mg·kg‐1
Trial: 31575825
Drug: Caffeine 2
RxNorm normalized name: caffeine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 2 mg·kg‐1
Trial: 26673692
Drug: Ganglioside consumption
RxNorm normalized name: IMMUNOGLOBULIN G1, ANTI-(GANGLIOSIDE GD2) (HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 LIGHT CHAIN, DIMER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganglioside consumption (43 mg/d) in patients with IBD
Trial: 19565735
Drug: Combined moxibustion
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined moxibustion and medicine group (n = 22)
Trial: 19565735
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine group (n = 29)
Trial: 19565735
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine group (n = 24)
Trial: 16505439
Drug: PEG‐IFNalpha‐2a (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFNalpha‐2a (all doses)
Trial: 14718821
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise program (therapy group) with physical therapy designed to strengthen calf musculature.
Trial: 2663318
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg acetaminophen
Trial: 17425493
Drug: Thrombolytic agents
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic agents
Trial: 2892989
Drug: (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) plus calcium (1 g/day)
Trial: 29702684
Drug: 100% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% oxygen inhalation (Control)
Trial: 23997689
Drug: Once weekly,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly, supervised hospital-based maintenance exercise plus home exercise for 12 months
Trial: 21941220
Drug: Ketamine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (intravenous loading dose 0.5 mg/kg followed by 9 μg/kg per minute for 20 mins)
Trial: 16470607
Drug: Prophylactic lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prophylactic lamivudine (100 mg daily before and until at least 8 weeks after chemotherapy)
Trial: 31221222
Drug: Gabapentin as
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin as add-on to morphine
Trial: 17768058
Drug: 7.2g alpha-ketoglutaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.2g alpha-ketoglutaric acid and 720 mg 5-hydroxymethylfurfural/day (SANOPAL) from days 1 to 10
Trial: 15229713
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of vitamins and minerals
Trial: 12109935
Drug: Sustained-release bupropion
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release bupropion (bupropion SR) 150mg twice daily
Trial: 12109935
Drug: Sustained-release bupropion
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release bupropion (bupropion SR) 300mg/day
Trial: 12109935
Drug: Sustained-release bupropion
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release bupropion (bupropion SR)
Trial: 9817266
Drug: CA10 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA10 with moderate/high dose-volume cardiac RT
Trial: 8176012
Drug: All tested
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All tested formulations
Trial: 12950862
Drug: Inhaled isoflurane
RxNorm normalized name: isoflurane Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled isoflurane
Trial: 26646404
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam and/or propofol
Trial: 20565044
Drug: Saint John's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saint John's Wort Extract (antidepressant treatment)
Trial: 15752403
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of thermal indicator into the right ventricle
Trial: 11560559
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg intravesical MMC plus local hyperthermia (Group 1)
Trial: 9623316
Drug: Cisapride, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride, 3 x 5 mg in a suspension one day before surgery and 30 mg 3 and 8 hours after surgery, followed by 2 x 30 mg in suppositories until oral ingestion is possible
Trial: 7910488
Drug: Antacid with
RxNorm normalized name: Antacid with Simethicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid with all agents tested
Trial: 24360107
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml normal saline infusion (placebo)
Trial: 24360107
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg parecoxib infusion
Trial: 18422481
Drug: Other antimuscarinic
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antimuscarinic agents
Trial: 10511061
Drug: DX-9065a (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DX-9065a (0.625 to 30 mg, intravenously administered)
Trial: 7654164
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of trust and explanation
Trial: 7195414
Drug: Nalidixic acid
RxNorm normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nalidixic acid (1 g four times a day) for 14 days
Trial: 7195414
Drug: Cephalexin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin (500 mg four times a day) for 14 days
Trial: 7195414
Drug: Cephalexin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin (500 mg four times a day) for 3 days
Trial: 30782673
Drug: Buried intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buried intradermal suture (BIS)
Trial: 28592063
Drug: Cisatracurium (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium (0.15 mg/kg) with end-tidal sevoflurane concentration at 2.5%
Trial: 28592063
Drug: Cisatracurium (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium (0.15 mg/kg) with end-tidal sevoflurane concentration at 3.0%
Trial: 11465619
Drug: Propofol (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (target concentration, 1.5 microg/ml)
Trial: 11465619
Drug: Alfentanil (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (12.5 microg/kg intravenous followed by 25 microg.kg(‐1).h(‐1))
Trial: 7604347
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection alone
Trial: 7604347
Drug: Laminectomy for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laminectomy for failed intradiscal injection
Trial: 2196144
Drug: Quinapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (20 mg) administered twice daily for 4 weeks
Trial: 517713
Drug: Glycopyrrolate 0.6
RxNorm normalized name: glycopyrrolate 0.6 MG in 3 mL Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate 0.6 mg and Neostigmine 2.5 mg i.v.
Trial: 517713
Drug: Glycopyrrolate 0.6
RxNorm normalized name: glycopyrrolate 0.6 MG in 3 mL Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate 0.6 mg and Neostigmine 5 mg i.v.
Trial: 30325613
Drug: Artificial urethral
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial urethral sphincter (AUS) implant 'BR - SL - AS - 904'
Trial: 20233182
Drug: R‐(‐)‐MA 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R‐(‐)‐MA 0.25 mg kg(‐1)
Trial: 20233182
Drug: S‐(+)‐MA 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐(+)‐MA 0.25 mg kg(‐1)
Trial: 14683659
Drug: Abacavir-lamivudine-tenofovir combination
RxNorm normalized name: abacavir / lamivudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abacavir-lamivudine-tenofovir combination treatment
Trial: 1497770
Drug: Single-dose cefuroxim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose cefuroxim (Zinacef)
Trial: 6836645
Drug: Nimodipine infusion
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine infusion (1 microgram kg-1 min-1)
Trial: 2859782
Drug: Once-daily treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily treatment (n = 97)
Trial: 2859782
Drug: Twice-daily treatment
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily treatment (n = 47)
Trial: 2859782
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily (n = 48)
Trial: 30051198
Drug: Pasireotide-LAR (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide-LAR (40 mg/4 weeks)
Trial: 27966503
Drug: Herbal formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal formulation toothpaste
Trial: 24730399
Drug: Topical tetracaine
RxNorm normalized name: tetracaine Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tetracaine hydrochloride 1%
Trial: 15778231
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus acupuncture
Trial: 12564745
Drug: Fast-melting tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-melting tablet
Trial: 12564745
Drug: Soft gelatin
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gelatin preparation
Trial: 16533451
Drug: Intramuscular oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular oxytocin 10 IU
Trial: 1346558
Drug: Pyridostigmine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (30 mg 3 times daily)
Trial: 30577902
Drug: Methadone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone treatment in jail-based program
Trial: 30577902
Drug: Methadone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone treatment in community programs
Trial: 26581034
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection (control phase)
Trial: 6203024
Drug: Multimodal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal therapy (chemotherapy + multiple fractionated radiation therapy)
Trial: 6203024
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily fractionated radiation therapy
Trial: 6203024
Drug: Single-modality therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-modality therapy (chemotherapy alone or radiation therapy alone)
Trial: 30659041
Drug: TN‐TC11LM (THC:CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TN‐TC11LM (THC:CBD in 1:1 ratio) capsules daily for 12 weeks
Trial: 30659041
Drug: TN‐TC19LM (THC:CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TN‐TC19LM (THC:CBD in 1:9 ratio) capsules daily for 12 weeks
Trial: 30659041
Drug: TN‐TC11LM and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TN‐TC11LM and TN‐TC19LM capsules
Trial: 29437074
Drug: Dexmedetomidine (self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (self-administered sedation)
Trial: 22078345
Drug: L-ornithine-L-aspartate (LOLA)
RxNorm normalized name: ornithine, (L)-isomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine-L-aspartate (LOLA)
Trial: 18201764
Drug: Perifosine 100
RxNorm normalized name: acetaminophen / phenyltoloxamine citrate Oral Tablet [Perisine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perifosine 100 mg daily or 900 mg weekly in combination with imatinib
Trial: 18201764
Drug: Topical steroids,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroids, topical antibiotics, and lubricating drops